KAUST's Computational Bioscience Research Center (CBRC) and King Abdulaziz City for Science and Technology (KACST) have collaborated on research into methicillin-resistant Staphylococcus aureus (MRSA) within Saudi Arabia, starting in July 2018. The two-year project aims to understand MRSA drug resistance mechanisms specific to the Kingdom and its regions, with the goal of developing public health strategies. The project involves sequencing samples and performing bioinformatics analysis to support a network of researchers in the country. Why it matters: This initiative enhances Saudi Arabia's capacity to predict, prevent, and control infectious diseases, aligning with national health objectives and building local expertise in computational bioscience.
KAUST and King Faisal Specialist Hospital and Research Centre (KFSH&RC) are collaborating to develop bioelectronic sensors for rapid pathogen detection. These sensors aim to provide cheap and accurate results, potentially replacing conventional lab tests. A COVID-19 saliva test developed by KAUST researchers showed comparable sensitivity to PCR tests with a 15-minute turnaround. Why it matters: This partnership accelerates the development of novel diagnostic tools, which could improve healthcare accessibility in remote areas and low-income countries within the region.
KAUST's Bioscience Core Lab (BCL) supports regional and global health initiatives through industry partnerships, offering expertise and technology access to organizations like SaudiVax. BCL aids SaudiVax in developing vaccines and monoclonal antibodies tailored to the needs of Saudi Arabia and the MENA region, focusing on respiratory diseases like MERS and COVID-19. SaudiVax is also collaborating with KAUST to research a new preventative drug targeting SARS-CoV-2. Why it matters: This strengthens Saudi Arabia's capabilities in vaccine development and biomanufacturing, addressing critical healthcare needs in the region and reducing reliance on external sources.
SaudiVax, located in the KAUST Research & Technology Park, is collaborating with the University of Pittsburgh and Merck France to develop a COVID-19 antibody injection. The antibody both protects against potential infection and neutralizes the virus in those already infected. SaudiVax is utilizing KAUST expertise and has contracted with Merck France for manufacturing since suitable facilities are not yet available in Saudi Arabia. Why it matters: This partnership highlights the growing biopharmaceutical capabilities in Saudi Arabia and the potential for KAUST to serve as a hub for medical innovation in the region.
KAUST and Janssen Pharmaceutical (Johnson & Johnson) are collaborating to research and innovate in neglected tropical diseases, focusing on dengue fever. They signed an MoU to establish a dengue fever research program and an infectious disease R&D center at KAUST's National BioPark. The partnership marks Johnson & Johnson's first university collaboration in Saudi Arabia. Why it matters: This collaboration signifies a major step in localizing disease research within Saudi Arabia and leveraging KAUST's AI, genomics, and data simulation expertise to address global health challenges.